We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (204)5/26/2004 11:45:40 AM
From: tuck  Read Replies (1) | Respond to of 255
Recent freebie editorial on inhaled insulin:

Notable for the sentence:

"Formation of anti-insulin antibodies is higher with inhaled insulin, and although this is dismissed as not affecting insulin requirement over time, older diabetologists will remember the drive to reduce insulin antibody formation, with the fears that antibodies delay and render unpredictable insulin absorption and even that antibody-antigen complexes may increase risk of microvascular disease."

I think this will torpedo Exubera, too, unless long term study data that does not reflect the Novo/Aradigm experience is also submitted. I hear that relevant study data was submitted by Pfizer to EMEA, but I thought these long term studies were still ongoing.

Cheers, Tuck